Category: Advances in Bioanalytics and Biomarkers
A novel isotope-dilution method using an Agilent RapidFire system coupled to a triple quadrupole mass spectrometer for the quantification of small molecule analytes in biological fluid specimens such as serum and urine has been developed. A series of 8 individual injections per specimen are performed at 8 different concentrations of stable isotope internal standard enabling the creation of a unique calibration curve for each specimen. The sample preparation is straightforward and can be performed manually or easily automated on a variety of liquid handling platforms. The creation of a unique standard curve for each specimen enables any specimen-specific matrix effects to be effectively normalized while the analysis of the analyte in octuplicate provides data with excellent statistical reliability. A batch of up to 12 specimens can be analyzed in under 15 minutes providing fast data turnaround in support of preclinical experiments particularly in the quantification of markers and biomarkers in animal models of disease. The throughput of the method enables same-day analytical reporting from hundreds of serum or urine samples facilitating tracking of the progress of preclinical studies in real time. Analytical data from the quantification of phenylalanine and tyrosine from several thousand mouse serum specimens collected and ran over several months in support of a series of preclinical studies will be presented. A creatinine assay using the same approach has been developed to normalize urinary analyte concentrations for variability due to urine dilution. Application of this novel approach to a range of amino acids, metabolites, and other small molecule analytes in serum and urine will be discussed and examples presented.
Can Ozbal– President and CEO, Purehoney Technologies, Billerica, MA
President and CEO
Dr. Özbal is responsible for much of the development of the RapidFire High-throughput Mass Spectrometry platform, invented at BioTrove, Inc. where he was Vice President and General Manager of the RapidFire business unit. He led the successful spinout of the RapidFire business to form an independent company, Biocius Life Sciences, in 2009 where he served as the Chief Operating Officer. In 2011 Biocius was acquired by Agilent Technologies and Dr. Özbal become Senior Director, RapidFire Products and the senior manager of the Agilent Wakefield, MA facility. He has extensive experience in bioanalytical chemistry, chromatography, spectroscopy and instrumentation design. Previously, Dr. Özbal was on the faculty of the Division of Bioengineering and Environmental Health (now part of the Department of Biological Engineering) at the Massachusetts Institute of Technology. He holds an A.B. with honors from Bowdoin College and a Ph.D. in Toxicology from Massachusetts Institute of Technology.